by Peter Ciszewski | Dec 22, 2022
Eva Morava-Kozicz, MD, PhD, of the Mayo Clinic in Rochester, MN, discusses why it is difficult to quickly diagnoise congenital disorders of glycosylation (CDG). CDG are rare genetic disorders that impact glycosylation, a natural process in which sugar...
by Peter Ciszewski | Dec 21, 2022
Ryan Jacobs, MD, from the Atrium Health Levine Cancer Institute in Charlotte, North Carolina, discusses 4-year follow up data from the phase 2 CAPTIVATE study, which evaluated ibrutinib plus venetoclax as a first-line treatment for chronic lymphocytic leukemia...
by Peter Ciszewski | Dec 15, 2022
Adam Lamble, MD, at the Cancer and Blood Disorders Center, Seattle Children’s Hospital, discusses a new study showing that pathogenic TP53 mutations, while rare, are associated with a poor prognosis in pediatric acute myeloid leukemia (AML). These findings were...
by Peter Ciszewski | Dec 13, 2022
Ryan Jacobs, MD, of the Atrium Health Levine Cancer Institute in Charlotte, NC discusses the need for real world data to access treatment efficacy in patients with chronic lymphocytic leukemia (CLL). Dr. Jacob also summarizes the results of a retrospective...
by Peter Ciszewski | Dec 12, 2022
Martin Dreyling, MD, of the LMU University Hospital Munich, in Munich, Germany discusses new data presented at a plenary lecture presented at ASH 2022 showing ibrutinib without autologous stem cell transplantation (ASCT) is as effective as ASCT to treat...
